Epidermal growth factor receptor tyrosine kinase inhibitors and depression.

[1]  G. Demetri,et al.  Small molecule tyrosine kinase inhibitor and depression. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Seth Wolpin,et al.  Depression screening using the Patient Health Questionnaire‐9 administered on a touch screen computer , 2009, Psycho-oncology.

[3]  N. Weiss,et al.  Incidence of suicide in persons with cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Mogun,et al.  Cancer and the risk of suicide in older Americans. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Fallon,et al.  Better off dead: suicidal thoughts in cancer patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Bezjak,et al.  Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Kris,et al.  Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.